Goldman Sachs: Edwards Lifesciences EW Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 466 M | Compra |
5,400,474
+851,361
| +19% | +USD 75.7 M | 0.04% | 403 |
|
|
2026
Q2 | USD 412 M | Venta |
4,549,113
-532,937
| -10% | -USD 44.6 M | 0.04% | 467 |
|
|
2026
Q1 | USD 407 M | Compra |
5,082,050
+1,778,338
| +54% | +USD 147 M | 0.05% | 404 |
|
|
2025
Q4 | USD 282 M | Compra |
3,303,712
+424,217
| +15% | +USD 34.8 M | 0.03% | 499 |
|
|
2025
Q3 | USD 224 M | Compra |
2,879,495
+149,647
| +5% | +USD 11.7 M | 0.03% | 559 |
|
|
2025
Q2 | USD 214 M | Compra |
2,729,848
+175,779
| +7% | +USD 13.1 M | 0.03% | 543 |
|
|
2025
Q1 | USD 185 M | Compra |
2,554,069
+361,111
| +16% | +USD 25.8 M | 0.03% | 539 |
|
|
2024
Q4 | USD 162 M | Venta |
2,192,958
-1,021,219
| -32% | -USD 71.5 M | 0.03% | 579 |
|
|
2024
Q3 | USD 212 M | Venta |
3,214,177
-790,194
| -20% | -USD 57.4 M | 0.03% | 495 |
|
|
2024
Q2 | USD 370 M | Compra |
4,004,371
+504,177
| +14% | +USD 44.6 M | 0.06% | 307 |
|
|
2024
Q1 | USD 334 M | Venta |
3,500,194
-12,951
| -0.4% | -USD 1.09 M | 0.06% | 335 |
|
|
2023
Q4 | USD 268 M | Compra |
3,513,145
+52,282
| +2% | +USD 3.64 M | 0.05% | 391 |
|
|
2023
Q3 | USD 240 M | Venta |
3,460,863
-1,257,981
| -27% | -USD 101 M | 0.05% | 363 |
|
|
2023
Q2 | USD 445 M | Venta |
4,718,844
-16,818
| -0.4% | -USD 1.46 M | 0.1% | 189 |
|
|
2023
Q1 | USD 392 M | Compra |
4,735,662
+1,308,749
| +38% | +USD 103 M | 0.09% | 214 |
|
|
2022
Q4 | USD 256 M | Compra |
3,426,913
+166,698
| +5% | +USD 12.8 M | 0.06% | 337 |
|
|
2022
Q3 | USD 269 M | Compra |
3,260,215
+249,875
| +8% | +USD 24 M | 0.07% | 288 |
|
|
2022
Q2 | USD 286 M | Compra |
3,010,340
+506,630
| +20% | +USD 52.4 M | 0.07% | 267 |
|
|
2022
Q1 | USD 295 M | Venta |
2,503,710
-305,591
| -11% | -USD 34.3 M | 0.06% | 307 |
|
|
2021
Q4 | USD 364 M | Compra |
2,809,301
+38,704
| +1% | +USD 4.51 M | 0.07% | 268 |
|
|
2021
Q3 | USD 314 M | Compra |
2,770,597
+397,721
| +17% | +USD 45.4 M | 0.07% | 277 |
|
|
2021
Q2 | USD 246 M | Venta |
2,372,876
-384,211
| -14% | -USD 36.2 M | 0.06% | 336 |
|
|
2021
Q1 | USD 231 M | Venta |
2,757,087
-247,748
| -8% | -USD 20.9 M | 0.06% | 325 |
|
|
2020
Q4 | USD 274 M | Venta |
3,004,835
-1,770,053
| -37% | -USD 147 M | 0.07% | 254 |
|
|
2020
Q3 | USD 381 M | Venta |
4,774,888
-800,989
| -14% | -USD 62.5 M | 0.11% | 166 |
|
|
2020
Q2 | USD 385 M | Venta |
5,575,877
-157,579
| -3% | -USD 11.2 M | 0.12% | 157 |
|
|
2020
Q1 | USD 360 M | Compra |
5,733,456
+323,949
| +6% | +USD 23.4 M | 0.13% | 147 |
|
|
2019
Q4 | USD 421 M | Compra |
5,409,507
+1,835,040
| +51% | +USD 143 M | 0.11% | 187 |
|
|
2019
Q3 | USD 262 M | Venta |
3,574,467
-785,721
| -18% | -USD 55.2 M | 0.08% | 284 |
|
|
2019
Q2 | USD 269 M | Compra |
4,360,188
+358,740
| +9% | +USD 21.7 M | 0.08% | 262 |
|
|
2019
Q1 | USD 255 M | Compra |
4,001,448
+397,296
| +11% | +USD 22.7 M | 0.08% | 264 |
|
|
2018
Q4 | USD 184 M | Venta |
3,604,152
-1,187,865
| -25% | -USD 60.1 M | 0.06% | 338 |
|
|
2018
Q3 | USD 278 M | Venta |
4,792,017
-744,294
| -13% | -USD 36.4 M | 0.07% | 292 |
|
|
2018
Q2 | USD 269 M | Venta |
5,536,311
-1,904,586
| -26% | -USD 88.9 M | 0.07% | 274 |
|
|
2018
Q1 | USD 346 M | Compra |
7,440,897
+409,626
| +6% | +USD 17.8 M | 0.09% | 243 |
|
|
2017
Q4 | USD 264 M | Compra |
7,031,271
+593,730
| +9% | +USD 21.8 M | 0.06% | 347 |
|
|
2017
Q3 | USD 235 M | Venta |
6,437,541
-1,517,553
| -19% | -USD 57.9 M | 0.06% | 361 |
|
|
2017
Q2 | USD 314 M | Compra |
7,955,094
+95,592
| +1% | +USD 3.49 M | 0.08% | 240 |
|
|
2017
Q1 | USD 246 M | Compra |
7,859,502
+945,735
| +14% | +USD 29.6 M | 0.07% | 305 |
|
|
2016
Q4 | USD 216 M | Compra |
6,913,767
+634,110
| +10% | +USD 20.5 M | 0.06% | 367 |
|
|
2016
Q3 | USD 252 M | Compra |
6,279,657
+2,642,772
| +73% | +USD 100 M | 0.08% | 255 |
|
|
2016
Q2 | USD 121 M | Venta |
3,636,885
-1,320,789
| -27% | -USD 45.2 M | 0.04% | 559 |
|
|
2016
Q1 | USD 146 M | Venta |
4,957,674
-999,741
| -17% | -USD 27.6 M | 0.05% | 476 |
|
|
2015
Q4 | USD 157 M | Compra |
5,957,415
+2,059,077
| +53% | +USD 53.5 M | 0.05% | 449 |
|
|
2015
Q3 | USD 92.4 M | Venta |
3,898,338
-575,364
| -13% | -USD 13.9 M | 0.03% | 663 |
|
|
2015
Q2 | USD 106 M | Compra |
4,473,702
+937,902
| +27% | +USD 21.2 M | 0.03% | 624 |
|
|
2015
Q1 | USD 84 M | Compra |
3,535,800
+1,402,068
| +66% | +USD 31.5 M | 0.03% | 739 |
|
|
2014
Q4 | USD 45.3 M | Compra |
2,133,732
+787,998
| +59% | +USD 15.8 M | 0.01% | 1187 |
|
|
2014
Q3 | USD 22.9 M | Venta |
1,345,734
-89,106
| -6% | -USD 1.41 M | 0.01% | 1694 |
|
|
2014
Q2 | USD 20.5 M | Venta |
1,434,840
-149,550
| -9% | -USD 2.03 M | 0.01% | 1761 |
|
|
2014
Q1 | USD 19.6 M | Venta |
1,584,390
-286,434
| -15% | -USD 3.31 M | 0.01% | 1783 |
|
|
2013
Q4 | USD 20.5 M | Venta |
1,870,824
-8,978,628
| -83% | -USD 101 M | 0.01% | 1726 |
|
|
2013
Q3 | USD 126 M | Compra |
10,849,452
+7,001,370
| +182% | +USD 81.9 M | 0.05% | 482 |
|
|
2013
Q2 | USD 43.1 M | Compra |
+3,848,082
| Nuevas | +USD 45.5 M | 0.02% | 996 |
|
Otros fondos que tienen EW en su portafolio
Posición de Goldman Sachs en EW: resumen de T3 2026
Goldman Sachs aumentó su participación en Edwards Lifesciences (EW) en 19% durante T3 2026, al comprar aproximadamente USD 75.7 M y elevar la posición a 5,400,474 acciones con un valor de USD 466 M. La posición representa 0.04% del portafolio y ocupa el puesto #403.
Goldman Sachs reportó por primera vez una posición en EW en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 1,345 fondos que sigue Wall St. Rank mantienen una posición en EW.
- Al cierre de T3 2026, Goldman Sachs tenía 5,400,474 acciones de Edwards Lifesciences con un valor de USD 466 M.
- Goldman Sachs compró 851,361 acciones de Edwards Lifesciences en T3 2026, por un monto estimado de USD 75.7 M.
- Edwards Lifesciences representó el 0.04% del portafolio de Goldman Sachs en T3 2026 y fue su posición número 403.
- Goldman Sachs reportó por primera vez una posición en Edwards Lifesciences en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 1,345 fondos que sigue Wall St. Rank tenían Edwards Lifesciences en su portafolio.
Según el informe 13F de Goldman Sachs correspondiente a T3 2026, presentado el 16 nov 2026.